PTC Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-14.3%projected annual EPS growth
Analyst Coverage
14analysts covering
FY Revenue (est.)
$1.3Bnext fiscal year
FY EPS (est.)
$1.60next fiscal year
Monitoring Framework
Key Performance Indicators
Global Sephience (sepiapterin) Net Product Revenue Quarterly124.6MTarget: Sustained launch momentum and expansion to up to 30 countries by year-end 2026
Total Net Product Revenue Quarterly225.6MTarget: $750 million to $850 million for full-year 2026
Total Revenue (including royalties and collaborations) Quarterly272.6MTarget: $1.08 billion to $1.18 billion for full-year 2026
Watch Items
- Regulatory review and potential approval of vatiquinone for Friedreich's ataxiaTrigger: FDA NDA decision / regulatory actionAction: Monitor regulatory milestones and prepare commercial launch infrastructure upon approval
- Translarna (ataluren) regulatory status and NDA reviewTrigger: FDA regulatory feedback or decisionAction: Assess impact on DMD franchise revenue and adjust commercial strategy accordingly
- PTC518 clinical development in Huntington's diseaseTrigger: Initiation of Phase 3 INVEST-HD study or updates on Novartis partnershipAction: Evaluate long-term pipeline value and potential milestone payments
Research as of 19 Jun 2026